Literature DB >> 26146540

Novel oral taxane therapies: recent Phase I results.

John Paul Flores1, M Wasif Saif2.   

Abstract

The oral taxanes are analogues of existing taxanes with a possible broad range of antitumor activity. They also have the potential advantages of ease of administration, better efficacy and lesser toxicity than currently available taxanes. These drugs have been used in several Phase I clinical trials, the methodology and results of which will be reviewed here.

Entities:  

Keywords:  BMS-275183; DHP107; ModraDoc001; milataxel; oral taxanes; ortataxel; tesetaxel

Year:  2013        PMID： 26146540      PMCID： PMC4489850          DOI： 10.4155/cli.13.18

Source DB:  PubMed          Journal:  Clin Investig (Lond)        ISSN： 2041-6792


  20 in total

1.  IDN5109, a taxane with oral bioavailability and potent antitumor activity.

Authors:  M I Nicoletti; T Colombo; C Rossi; C Monardo; S Stura; M Zucchetti; A Riva; P Morazzoni; M B Donati; E Bombardelli; M D'Incalci; R Giavazzi
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

Review 2.  Novel formulations of taxanes: a review. Old wine in a new bottle?

Authors:  K L Hennenfent; R Govindan
Journal:  Ann Oncol       Date:  2005-12-19       Impact factor: 32.976

3.  Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

Authors:  J J Moes; S L W Koolen; A D R Huitema; J H M Schellens; J H Beijnen; B Nuijen
Journal:  Int J Pharm       Date:  2011-09-02       Impact factor: 5.875

4.  Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.

Authors:  C M F Kruijtzer; J H M Schellens; J Mezger; M E Scheulen; U Keilholz; J H Beijnen; H Rosing; R A A Mathôt; S Marcus; H van Tinteren; P Baas
Journal:  J Clin Oncol       Date:  2002-12-01       Impact factor: 44.544

5.  Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.

Authors:  A C Lockhart; R Bukowski; M L Rothenberg; K K Wang; W Cooper; J Grover; L Appleman; P R Mayer; M Shapiro; A X Zhu
Journal:  Cancer Chemother Pharmacol       Date:  2006-11-08       Impact factor: 3.333

6.  MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.

Authors:  Deepak Sampath; Carolyn M Discafani; Frank Loganzo; Carl Beyer; Hao Liu; Xingzhi Tan; Sylvia Musto; Tami Annable; Patricia Gallagher; Carol Rios; Lee M Greenberger
Journal:  Mol Cancer Ther       Date:  2003-09       Impact factor: 6.261

7.  Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer.

Authors:  Paul Baas; A Szczesna; I Albert; J Milanowski; E Juhász; Z Sztancsik; J von Pawel; R Oyama; S Burgers
Journal:  J Thorac Oncol       Date:  2008-07       Impact factor: 15.609

8.  A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer.

Authors:  Ramesh K Ramanathan; Joel Picus; Haralambos Raftopoulos; Stephen Bernard; A Craig Lockhart; Gary Frenette; John Macdonald; Susan Melin; Daniel Berg; Frank Brescia; Howard Hochster; Allen Cohn
Journal:  Cancer Chemother Pharmacol       Date:  2007-05-22       Impact factor: 3.333

9.  A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183.

Authors:  Linda E Bröker; Stephan A Veltkamp; Elisabeth I Heath; Bart C Kuenen; Helen Gall; Ludovic Astier; Susan Parker; Louis Kayitalire; Patricia M Lorusso; Jan H M Schellens; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

10.  Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.

Authors:  H H Helgason; C M F Kruijtzer; A D R Huitema; S G Marcus; W W ten Bokkel Huinink; M E Schot; J H Schornagel; J H Beijnen; J H M Schellens
Journal:  Br J Cancer       Date:  2006-09-12       Impact factor: 7.640
View more
  6 in total

Review 1.  Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products.

Authors:  April L Risinger; Lin Du
Journal:  Nat Prod Rep       Date:  2019-11-25       Impact factor: 13.423

Review 2.  Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.

Authors:  Christopher C Mills; E A Kolb; Valerie B Sampson
Journal:  Cancer Res       Date:  2017-11-02       Impact factor: 12.701

3.  Absorption mechanism of DHP107, an oral paclitaxel formulation that forms a hydrated lipidic sponge phase.

Authors:  Yura Jang; Hye Jin Chung; Jung Wan Hong; Cheol-Won Yun; Hesson Chung
Journal:  Acta Pharmacol Sin       Date:  2016-11-21       Impact factor: 6.150

4.  Optimization Of Cancer Treatment Through Overcoming Drug Resistance.

Authors:  Yahya I Elshimali; Yong Wu; Hussein Khaddour; Yanyuan Wu; Daniela Gradinaru; Hema Sukhija; Seyung S Chung; Jaydutt V Vadgama
Journal:  J Cancer Res Oncobiol       Date:  2018-02-27

Review 5.  Perplexing Role of P-Glycoprotein in Tumor Microenvironment.

Authors:  Kianna Robinson; Venkataswarup Tiriveedhi
Journal:  Front Oncol       Date:  2020-03-05       Impact factor: 6.244

Review 6.  Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment.

Authors:  Joan Tymon-Rosario; Naomi N Adjei; Dana M Roque; Alessandro D Santin
Journal:  Cancers (Basel)       Date:  2021-12-12       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.